The utility of polygenic risk scores (PRSs) is gaining researchers' attention for identifying individual genetic risk and disease risk prediction in Alzheimer's disease (AD) at both the early and pre-symptomatic stages of the disease. genoSCORE™ combines Cytox's proprietary technology variaTECT™, a single nucleotide polymorphism (SNP) profiling array built on the Axiom platform from Thermo Fisher Scientific, with SNPfitR™ analytical and interpretive software incorporating algorithms developed in partnership with Cardiff University to give a PRS that identifies any individual's genetic risk of developing AD from blood or saliva-extracted DNA. This can help in patient stratification for clinical trial research to develop targeted treatments for AD.

Learning objectives:

• Select the highest risk APOE3/E4 subjects mostly likely to develop AD
• Identify highest/low risk APOE3/E3 subjects for inclusion/exclusion in clinical studies